Myriad Genetics, Inc. (MYGN) Tops Q2 EPS by 20c; Boosts FY14 Outlook
Tweet Send to a Friend
Myriad Genetics, Inc. (NASDAQ: MYGN) reported Q2 EPS of $0.66, $0.20 better than the analyst estimate of $0.46 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
